5:39 PM
 | 
Apr 30, 2013
 |  BC Extra  |  Top Story

Aveo plunges on tivozanib briefing docs

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) fell $2.33 (31%) to $5.11 on Tuesday after FDA reviewers questioned whether a single...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >